Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19. Chang LC, Chen IW, Hung KC. J Med Virol 2024;96:e29464.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chang LC, Chen IW, Hung KC. Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19. J Med Virol 2024;96:e29464.
PMID: 38329167